This preprint is under consideration at Gut Pathogens. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Wenzhu Dong
Qingdao 971 hospital
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
We aimed to assess a serological biopsy using five stomach-specific circulating biomarkers pepsinogen I (PGI), PGII, PGI/II ratio, anti- Helicobacter pylori (H. pylori) antibody, and gastrin-17 (G-17) for identifying high-risk individuals and predicting risk of developing gastric cancer (GC).
Results
In the cross-sectional analysis, PGII, the PG ratio, G17, anti- H. pylori IgG were associated with the presence of CAG, and the five biomarkers combined prediction is more effective than single factor prediction (0.692 vs 0.54, 0.604, 0.616, 0.629).
Conclusion
The combination of pepsinogens, G17 and anti-H. pylori antibodies for serological analysis is helpful to screen CAG high-risk individuals from the general population and recommend that these people should carry out further endoscopy and biopsy.
Keywords
Macroscale Liquid, Mixtures of Glycerol, Diols
Figure 1
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
Version 1
Posted 23 Mar, 2021
No community comments so far
Editorial decision: Revise Before Review
On 23 Mar, 2021
First submitted
On 19 Mar, 2021
Editor assigned
On 18 Mar, 2021
Submission checks complete
On 18 Mar, 2021
Editor invited
On 18 Mar, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at Gut Pathogens. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Wenzhu Dong
Qingdao 971 hospital
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
Version 1
Posted 23 Mar, 2021
No community comments so far
Editorial decision: Revise Before Review
On 23 Mar, 2021
First submitted
On 19 Mar, 2021
Editor assigned
On 18 Mar, 2021
Submission checks complete
On 18 Mar, 2021
Editor invited
On 18 Mar, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
We aimed to assess a serological biopsy using five stomach-specific circulating biomarkers pepsinogen I (PGI), PGII, PGI/II ratio, anti- Helicobacter pylori (H. pylori) antibody, and gastrin-17 (G-17) for identifying high-risk individuals and predicting risk of developing gastric cancer (GC).
Results
In the cross-sectional analysis, PGII, the PG ratio, G17, anti- H. pylori IgG were associated with the presence of CAG, and the five biomarkers combined prediction is more effective than single factor prediction (0.692 vs 0.54, 0.604, 0.616, 0.629).
Conclusion
The combination of pepsinogens, G17 and anti-H. pylori antibodies for serological analysis is helpful to screen CAG high-risk individuals from the general population and recommend that these people should carry out further endoscopy and biopsy.
Figure 1
Loading...